The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Published version of a preprint
Abstract
Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) detects prostate cancer with superior sensitivity to conventional imaging, but its performance in nmCRPC remains largely unknown. We characterized cancer burden in high-risk patients with nmCRPC using PSMA-PET. Experimental Design: We retrospectively included 200 patients with nmCRPC, prostate-specific antigen (PSA) >2 ng/mL, and high risk for metastatic disease [PSA doubling time (PSADT) of ≤10 months and/or Gleason score of ≥8] from six high-volume PET centers. We centrally reviewed PSMA-PET detection rate for pelvic disease and distant metastases (M1). We further evaluated SPARTAN patients stratified by risk factors for PSMA-PET-detected M1 disease. Results: PSMA-PET was positive in 196 of 200 patients. Overall, 44% had pelvic diseases, including 24% with local prostate bed recurrence, and 55% had M1 disease despite negative conventional imaging. Interobserver agreement was very high (κ: 0.81–0.91). PSA ≥ 5.5 ng/mL, locoregional nodal involvement determined by pathology (pN1), prior primary radiation, and prior salvage radiotherapy independently predicted M1 disease (all P < 0.05). Conclusions: PSMA-PET detected any disease in nearly all patients and M1 disease in 55% of patients previously diagnosed with nmCRPC, including subgroups with PSADT of ≤10 months and Gleason score of ≥8. The value of PSMA-PET imaging for treatment guidance should be tested in future studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of more sensitive PSMA PET imaging, now routine in clinical practice, may identify metastases in patients that previously would have been classified as having M0 CRPC with conventional imaging [93].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [93]
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationApalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344 · cited 11×
“Apalutamide and enzalutamide have been approved for the treatment of nmCRPC based on demonstration of a significant improvement in metastasis-free survival (MFS) in the SPARTAN and PROSPER studies (5, 6).”
BackgroundInfluentialSelf-citationEnzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Self-citationDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930 · cited 2×
“M1b (bone) 47 (24) 26 (23) 21 (25) M1c (visceral) 12 (6) 8 (7) 4 (5)”
BackgroundSelf-citationFendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779
Self-citation68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., Giesel, F., Haberkorn, U., Hope, T. A., Kopka, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3670-z · Cited by 750
Self-citationEiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626
Self-citationEAU Guidelines on Prostate Cancer
Aus, G., Abbou, C. C., Bolla, M., Heidenreich, A., Schmid, H.-P., van Poppel, H., Wolff, J., & Zattoni, F. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.001 · Cited by 579
Research works printed but not linked: 1
- Hope, 2018, Meta-analysis of 68Ga-PSMA-11 PET with a focus on pathology correlation, J Nucl Med, 59, 1714
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationSandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003892 · Cited by 428
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Calais, J., Ceci, F., Cho, S. Y., Fanti, S., Giesel, F. L., Goffin, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06089-w · Cited by 410
Self-citation
Metadata
- Authors
- Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., Perez, P. M., Hope, T. A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., & Hadaschik, B.
- Affiliations
- University of California, Los Angeles (US)
- Essen University Hospital (DE)
- Peter MacCallum Cancer Centre (AU)
- Ludwig-Maximilians-Universität München (DE)
- 5Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.
- University of California, San Francisco (US)
- Harvard University (US)
- TUM Klinikum (DE)
- 9Janssen Research & Development, Titusville, New Jersey.
- 10Janssen Research & Development, Los Angeles, California.
- Janssen Research & Development (United States) (US)
- Universität Hamburg (DE)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2019-12-13
- Volume
- 25
- Issue
- 24
- Pages
- 7448-7454
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2972890374
- Cited by
- 266
- References
- 28
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 40 · 2023: 43 · 2022: 41 · 2021: 55 · 2020: 38 · 2019: 3
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- German Research Foundation (FE1573/1-1/807122 and FE1573/3-1/659216)
- Mercator Research Center Ruhr (An-2019-0001)
- IFORES (D/107-81260, D/107-30240)
- Topics
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- prostate-specific membrane antigen, PSMA PET, non-metastatic castration-resistant prostate cancer, distant metastasis, pelvic diseases, androgen deprivation therapy, SPARTAN trial, Gleason score, PSA doubling time, salvage radiotherapy, prior radiation, metastasis detection
- MeSH terms
- Positron Emission Tomography Computed Tomography, Aged, Aged, 80 and over, Androgen Antagonists, Antigens, Surface, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Neoplasm Grading, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1050
- The paper
- Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., Perez, P. M., Hope, T. A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., & Hadaschik, B. (2019). Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.